Siloam International Hospitals (SILO) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Siloam International Hospitals IDR 1,806, price IDR 2,090, upside -13.6%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Siloam International Hospitals for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 773.30 IDR – 3,750 IDR · fair‑value band 1,060 IDR – 2,347 IDR · the 2,090 IDR price screens above the 1,806 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Siloam International Hospitals in your weekly email
Every Wednesday you see whether Siloam International Hospitals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services.
Show more
PT Siloam International Hospitals Tbk operates hospitals and clinics in Indonesia. The company offers general, pre-marital, and lite checkups; male and female screenings; heart, kidney, and cancer screenings; visa application and preemployment screenings; and vaccine and genomic testing services. It also provides diagnostic services, including laboratory and radiology checks; home services; COVID-19 tests; radiation therapy; and teleconsultation services. In addition, it offers services in the areas of andrology, anesthesiology, and arrythmia; cardiothoracic, digestive, general, neuro, pediatric, plastic, and vascular surgery; cardiology, cardiovascular emergency and intensive care, cardiovascular imaging, pediatric cardiology and congenital heart diseases, and preventive cardiology and cardiac rehabilitation; clinical nutrition and psychology; medical acupuncture and laboratory; dermatology, venereology, and aesthetics; and echocardiography, internal medicine, interventional cardiology, neurology, nuclear medicine, obstetrics and gynecologist, occupational medicine, ophthalmology, orthopedic and traumatology, otorhinolaryngology, physical medicine and rehabilitation, pulmonology, radiation oncology, radiology, sports medicine, and urology. Further, it engages in trading, development, mining, agriculture, land transportation, printing, plantation, forestry, electrical, mechanical, engineering, construction, and real estate businesses; computer programming; software publishing and retail trading; provision of management consulting, retail, professional, and scientific and technical; web portal and/or digital platform business; workshops; leasing; wholesale trade; IT; and social services. The company was formerly known as PT Sentralindo Wirasta. PT Siloam International Hospitals Tbk was founded in 1996 and is headquartered in Tangerang, Indonesia. PT Siloam International Hospitals Tbk operates as a subsidiary of Sight Investment Company Pte. Limited.
Stock analysis
Siloam International Hospitals (SILO) currently trades at 2,090 IDR, while our model-based Fair Value estimate is 1,806 IDR, implying the stock looks roughly 15.8% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 1,994 IDR per share, and 8 of the 24 models we run sit above the 2,090 IDR price.
Bear case: the Asset-Based group reads lowest at 500.19 IDR, and 16 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 1,060 IDR (bear) to 2,347 IDR (bull), the price of 2,090 IDR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Siloam International Hospitals reported revenue of 12.8T IDR in FY2025 versus 9.4T IDR in FY2021, a compound +8.2%/yr. Reported net income was 1.1T IDR in FY2025, compounding +13.3%/yr from FY2021.
Key figures
Market cap 27.1T IDR (≈ $2.7B) · P/E ratio 23.7 · P/S ratio 2.05 · EPS (TTM) 88.34 IDR · Net margin 8.7% · Return on equity 12.5% · Return on assets (EBIT) 11.9% · Operating margin 12.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 27% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −14%, SILO screens richer than that median.
Fair Value models
Bear 1,060 IDRFair Value 1,806 IDRBull 2,347 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (64.62 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.87/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2020 (pandemic). Over 10 years: +12.0% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+23.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+23.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23% vs 28%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 14%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+29.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +26.0% a year for the price and +6.4% for the forecasts.
Compare Siloam International Hospitals with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−14% · Below median
Profitability
Return on equity (TTM)12% · Above median
Return on assets8% · Top 25%
Net margin (TTM)9% · Above median
Operating margin (TTM)13% · Above median
Growth and dividend
Revenue growth8% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Siloam International Hospitals Fair Value". https://www.fairvalue-calculator.com/stock/SILO
Frequently asked questions
Is Siloam International Hospitals (SILO) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,806 IDR versus a price of 2,090 IDR, about −14% upside (overvalued).
What is the fair value of SILO?
Our model-based fair value for Siloam International Hospitals is 1,806 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,090 IDR.
What is the quality score of SILO?
Siloam International Hospitals has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Siloam International Hospitals (SILO)?
Our model-based price target is the fair value of 1,806 IDR (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 1,060 IDR, optimistic scenario 2,347 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Siloam International Hospitals stock forecast for 2026?
Our models put fair value at 1,806 IDR, about −14% upside versus a price of 2,090 IDR (overvalued). Cautious scenario 1,060 IDR, optimistic scenario 2,347 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Siloam International Hospitals (SILO)?
Siloam International Hospitals reported trailing-twelve-month revenue of about 13.1T IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Siloam International Hospitals (SILO)?
For today's price to be fair in a discounted-cash-flow model, Siloam International Hospitals would have to grow free cash flow by +29.3 % per year for five years (discount rate 12.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SILO use?
Our models discount Siloam International Hospitals at 12.0 %: a base by market capitalisation (mid), country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Siloam International Hospitals that is +29.3 % per year a year over ten years, using the same discount rate (12.0 %) and the same formula as our fair value.
How much growth has Siloam International Hospitals (SILO) delivered so far?
Over the past 5 years revenue at Siloam International Hospitals grew +12.6 % a year. The price currently implies +29.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Siloam International Hospitals (SILO) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Siloam International Hospitals (+29.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Siloam International Hospitals (SILO)?
The free-cash-flow yield on the price is 2.47 %: that much free cash flow Siloam International Hospitals produces per unit of market value. When it exceeds the discount rate of our models (12.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Siloam International Hospitals (SILO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Siloam International Hospitals it is 1,806 IDR per share (as of Sep 24, 2026), against a price of 2,090 IDR. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Siloam International Hospitals stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SILO trades above its calculated fair value: price 2,090 IDR, fair value 1,806 IDR, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SILO?
No. The price is what the market pays today (2,090 IDR); the fair value is what the company's own numbers justify (1,806 IDR). For Siloam International Hospitals the two are 284.45 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Siloam International Hospitals worth?
The market values Siloam International Hospitals at about 27.1T IDR (market capitalisation, as of Sep 24, 2026). Per share that is 2,090 IDR; our models calculate a fair value of 1,806 IDR per share.
What do the bullish and bearish scenarios say about SILO?
Our models span a range for Siloam International Hospitals: cautious scenario 1,060 IDR, base 1,806 IDR, optimistic 2,347 IDR per share (as of Sep 24, 2026, price 2,090 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SILO?
Siloam International Hospitals trades at a price-to-earnings ratio of 23.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1,806 IDR is built from several models across several years. Other multiples: PEG 2.8, P/B 2.8, P/S 2.1, EV/EBITDA 11.4.
What is the PEG ratio of SILO?
The PEG ratio of Siloam International Hospitals is 2.82 (P/E divided by earnings growth, as of Sep 24, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Siloam International Hospitals (SILO)?
Balance-sheet figures for Siloam International Hospitals (as of Sep 24, 2026): return on equity 12.5%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is SILO from its 52-week high?
Siloam International Hospitals trades at 2,090 IDR, about 27% below its 52-week high of 2,880 IDR and 13% above the low of 1,845 IDR (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,806 IDR is for.
Which stocks are comparable to Siloam International Hospitals?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Siloam International Hospitals stock attractive at the current price?
The data as of Sep 24, 2026: price 2,090 IDR, calculated fair value 1,806 IDR (−14%), Quality Score 53/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SILO calculated?
We run Siloam International Hospitals through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,806 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Siloam International Hospitals itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Siloam International Hospitals (SILO)?
The closing price on Sep 23, 2026 was 2,090 IDR. Our model-based fair value is 1,806 IDR, about −14% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Siloam International Hospitals right now?
Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (1,060 IDR to 2,347 IDR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Where does the earnings growth of Siloam International Hospitals (SILO) come from?
Earnings per share at Siloam International Hospitals grew +30.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.5 %, EBIT margin +14.3 %, tax rate +2.3 %, residual (interest, one-offs) +2.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Siloam International Hospitals
How large is the market capitalisation of Siloam International Hospitals (SILO)?
The market capitalisation of Siloam International Hospitals is 27.1T IDR (≈ $2.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Siloam International Hospitals (SILO)?
The price-to-sales ratio of Siloam International Hospitals is 2.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Siloam International Hospitals (SILO)?
Earnings per share at Siloam International Hospitals are 88.34 IDR (price ÷ EPS = P/E 23.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Siloam International Hospitals (SILO)?
The net margin of Siloam International Hospitals is 8.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Siloam International Hospitals (SILO)?
The return on equity (ROE) of Siloam International Hospitals is 12.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Siloam International Hospitals (SILO)?
On an EBIT basis the return on assets of Siloam International Hospitals is 11.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Siloam International Hospitals (SILO)?
The operating margin of Siloam International Hospitals is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Siloam International Hospitals (SILO)?
Revenue at Siloam International Hospitals is growing +7.9% versus a year earlier (3y avg +10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Siloam International Hospitals (SILO)?
Earnings per share at Siloam International Hospitals are growing +13.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Siloam International Hospitals (SILO) carry?
The net debt of Siloam International Hospitals is 477B IDR (fiscal year 2025, ≈ 0.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Siloam International Hospitals in the live analysis
One click puts Siloam International Hospitals on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
